Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders
JCI Insight · 2025
DOI: 10.1172/jci.insight.199443 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Keaton J Solo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carnitine, Fatty Acids, Lipid Metabolism, Inborn Errors, Exercise Tolerance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, national institute of health.
Abstract (Originalsprache)
Long-chain fatty acid oxidation disorders (LC-FAODs) cause energy deficits in heart and skeletal muscle that are only partially corrected by current medium-chain lipid therapies such as triheptanoin. We find that heart and muscle lack medium-chain acyl-CoA synthetases, limiting the capacity for β-oxidation of medium-chain fatty acids. Instead, heart and muscle mitochondria robustly respire on medium-chain acylcarnitines. The mitochondrial matrix enzyme carnitine acetyltransferase (CrAT) efficiently converts orally delivered octanoylcarnitine (C8-carnitine) to octanoyl-CoA for energy generation. C8-carnitine exhibits twice the oral bioavailability of triheptanoin and distributes to muscle and heart. A single oral dose significantly enhances grip strength and treadmill endurance while attenuating lactic acidosis in 2 mouse models of LC-FAODs. Thus, medium-chain acylcarnitines overcome a previously unrecognized metabolic bottleneck in LC-FAOD muscle and may represent an alternative to triglyceride-based therapies for bioenergetic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Genetic and Genomic Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Pediatrics, University of Colorado Anschutz Medical Campus/Children's Hospital of Colorado, Aurora, Colorado, USA.
Förderung
- NIDDK NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- national institute of health
Zitieren
APA
Solo, K. J., Zhang, Y., Bharathi, S. S., Zhang, B. B., Richert, A. C., Schmidt, A. V., Van't Land, C., D'Annibale, O., Wood, T. C., & Goetzman, E. S. (2025). Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders. JCI Insight. https://doi.org/10.1172/jci.insight.199443
Vancouver
Solo KJ, Zhang Y, Bharathi SS, Zhang BB, Richert AC, Schmidt AV, et al. Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders. JCI Insight. 2025. doi:10.1172/jci.insight.199443
BibTeX
@article{Solo2025,
author = {Solo, Keaton J and Zhang, Yuxun and Bharathi, Sivakama S and Zhang, Bob B and Richert, Adam C and Schmidt, Alexandra V and Van't Land, Clinton and D'Annibale, Olivia and Wood, Timothy C and Goetzman, Eric S},
title = {Oral octanoylcarnitine alleviates exercise intolerance in mouse models of long-chain fatty acid oxidation disorders},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.199443}
}
EUVIMED